STAT+ wearable health tech Hinge Health FDA clearance migraine treatment neuromodulation device digital therapeutics chronic migraine non-pharmacological treatment health innovation

Hinge Health, a leading digital health company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its new wearable device for the treatment of migraines.

The device leverages non-invasive neuromodulation technology to provide relief from migraine symptoms. Unlike traditional pharmaceutical treatments, this approach offers a drug-free alternative for individuals suffering from chronic migraines.

This FDA clearance represents a major milestone for Hinge Health, which has been expanding its portfolio of digital therapeutic solutions. The company’s mission focuses on empowering patients to manage chronic conditions through innovative, evidence-based technologies.

Key details of the device:

  • Designed for migraine treatment and symptom management
  • Uses neuromodulation technology to target migraine pathways
  • Provides a non-pharmacological approach to migraine relief
  • Received FDA clearance for market availability

The clearance follows rigorous clinical evaluations to ensure safety and efficacy. Hinge Health plans to integrate the device into its broader digital health platform, offering patients a comprehensive solution for migraine management.

This development underscores the growing role of digital therapeutics in addressing unmet medical needs, particularly in chronic pain and neurological conditions.

Source: STAT News
Budweiser Celebrates 150 Years with Patriotic Campaign Tied to America’s 250th Anniversary
← Previous

Budweiser Celebrates 150 Years with Patriotic Campaign Tied to America...

 CRISPR Breakthroughs Offer Hope for Down Syndrome and Genetic Disorders Treatment
Next →

CRISPR Breakthroughs Offer Hope for Down Syndrome and Genetic Disorder...